ClariVest Asset Management’s XBiotech XBIT Stock Holding History

ClariVest Asset Management’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-162,006	Closed	-$3.02M	–	790
2019 Q4	$3.02M	Buy	+162,006	New	+$2.09M	0.07%	196

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

ClariVest Asset Management's XBIT Position: Q1 2020 in Review

ClariVest Asset Management sold out of XBiotech (XBIT) in Q1 2020, closing a stake of 162,006 shares — an estimated $3.02M sold.

ClariVest Asset Management first reported a position in XBIT in Q4 2019 and held it in 1 quarter. The position peaked at $3.02M in Q4 2019. 60 funds tracked by Wall St. Rank hold XBIT as of Q1 2020.

ClariVest Asset Management reported no remaining XBiotech position as of Q1 2020 after selling out during the quarter.
ClariVest Asset Management sold 162,006 XBiotech shares in Q1 2020, an estimated $3.02M.
ClariVest Asset Management first reported a position in XBiotech in Q4 2019 and held it in 1 quarter.
ClariVest Asset Management's XBiotech position peaked at $3.02M in Q4 2019.
60 funds tracked by Wall St. Rank held XBiotech as of Q1 2020.

Based on ClariVest Asset Management's 13F filing for Q1 2020, filed 4 May 2020.